Experiences in treatment of multiple sclerosis with natalizumab from a real-life cohort over 15 years

Experiences in treatment of multiple sclerosis with natalizumab from a real-life cohort over 15 years

Abstract Natalizumab (NTZ) has been used for treatment of highly active relapsing–remitting multiple sclerosis (MS). When stopping NTZ the risk of severe rebound phenomenon has to be considered. We aimed to investigate the use of NTZ in clinical routine and focused on identification of potential ris...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Michael Auer, Anne Zinganell, Harald Hegen, Gabriel Bsteh, Franziska Di Pauli, Klaus Berek, Elena Fava, Sebastian Wurth, Thomas Berger, Florian Deisenhammer
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Medicine
R
Science
Q
Acceso en línea:https://doaj.org/article/c9d665bf8d6647dd880506272321e181
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares